@article{aa85e6ba339049248bdfa5fdd61f8612,
title = "BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease",
author = "Ferdows Atiq and Karin Fijnvandraat and \{van Galen\}, \{Karin P. M.\} and \{Laros-van Gorkom\}, \{B. A. P.\} and Karina Meijer and \{de Meris\}, J. and Michiel Coppens and Mauser-Bunschoten, \{E. P.\} and Cnossen, \{M. H.\} and \{van der Bom\}, \{J. G.\} and Jeroen Eikenboom and Leebeek, \{F. W. G.\} and K. Fijnvandraat and M. Coppens and A. Kors and S. Zweegman and Goverde, \{G. J.\} and Jonkers, \{M. H.\} and N. Dors and Nijziel, \{M. R.\} and L. Nieuwenhuizen and K. Meijer and Tamminga, \{R. Y. J.\} and \{van der Linden\}, \{P. W.\} and Ypma, \{P. F.\} and Eikenboom, \{H. C. J.\} and Smiers, \{F. J. W.\} and B. Granzen and K. Hamulyak and P. Brons and F. Atiq and \{van Galen\}, \{K. P. M.\} and \{WiN Study Group\}",
note = "Funding Information: F. Atiq received the professor Heimburger Award 2018. F.W.G. Lee-beek received research support from CSL Behring and Shire/Takeda for performing the Willebrand in the Netherlands (WiN) study, and is consultant for uniQure, Novo Nordisk and Shire/Takeda, of which the fees go to the institution. J. Eikenboom received research support from CSL Behring and he has been a teacher on educational activities of Roche. K. P. M. van Galen received unrestricted research support from CSL Behring and Bayer. E.P. Mauser-Bunschoten received unrestricted research/ educational support from CSL Behring, Bayer, Baxter, Grifols, Novo Nordisk, Pfizer, Biotest, Roche and Sanquin. J.G. van der Bom has been a teacher on educational activities of Bayer. M.H. Cnossen has received unrestricted research/educational and travel funding from the following companies: Pfizer, Baxter, Bayer Schering Pharma, CSL Behring, Novo Nordisk and Novartis, and serves as a member on steering boards of Roche and Bayer of which fees go to the institution. K. Fijnvandraat is a member of the European Hemophilia Treatment and Standardization Board sponsored by Baxter, has received unrestricted research grants from CSL Behring and Bayer, and has given lectures at educational symposiums organized by Pfizer, Bayer and Baxter. K. Meijer received research support from Bayer, Sanquin and Pfizer; speaker fees from Bayer, Sanquin, Boehringer Ingelheim, BMS and Aspen; consulting fees from Uniqure, of which all fees go to the institution. B. Laros-van Gorkom has received unrestricted educational grants from Baxter and CSL Behring. M. Coppens has received research support, lecturing and consulting fees from Bayer, CSL Behring, UniQure, Sanquin and Sanofi. All fees were received by his institution. None of the other authors has a conflict of interest to declare. Funding Information: This study was supported (in part) by research funding from the Dutch Hemophilia Foundation (Stichting Hemophilia) and CSL Behring (unrestricted grant).",
year = "2019",
month = aug,
doi = "10.1002/ajh.25499",
language = "English",
volume = "94",
pages = "E201--E205",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "John Wiley \& Sons Inc.",
number = "8",
}